As the electric vehicle industry becomes more active There are a lot of companies that make electric car batteries In MEK, you can improve the quality of electric vehicle batteries.
Mediwhale Co Ltd.
Mediwhale is a company specializing in retinal AI biomarkers for predicting cardiovascular, renal, and metabolic risks. Our innovative technology enables a 30-second eye scan to accurately identify future risks of cardiovascular disease, chronic kidney disease, and existing ocular conditions, providing physicians and patients with actionable insights for preventive care. Mediwhale’s solutions are called “Dr. Noon” are already being utilized in clinical settings across South Korea, the EU, UK, Dubai, and other Asia regions, supported by regulatory approvals and a reimbursement code. Our technology is backed by robust clinical evidence, with key studies published in leading journals such as The Lancet Digital Health and European Heart Journal Digital Health. | Mediwhale leverages retinal imaging and AI to advance early detection, personalized risk assessment, and preventive care. Retinal AI enables the early identification of cardiometabolic risk, supporting proactive and preventive healthcare. Mediwhale offers the world’s first regulatory-approved AI solution for cardiovascular risk assessment using retinal imaging.
MEDINNOA
Medinnoa is a company whose name combines medicine, innovation, and a suffix denoting a place. It represents our mission to transform patient care including procedure/surgery through the integration of artificial intelligence and extended reality technologies.
MEDIFIC INC.
MEDIFC Inc. is a biotechnology company based in Korea devoted to developing first-in-class anti-cancer drugs to target cancer stem cell. About MEDIFIC Inc. MEDIFIC is a pre-clinical stage biotech company developing first-in-class anti-cancer drugs to target cancer stem cells (CSCs). MEDIFIC was founded in 2018, based on expertise in brain cancer and CSC research for over 20 years from academia (Korea University). MEDIFIC is dedicated to developing innovative anti-cancer drugs that can provide a better therapeutic opportunity to patients suffering from malignant cancers, especially glioblastoma (GBM) and intractable diseases. MEDIFIC takes an open innovation strategy to collaborate with expert groups in a variety of fields, such as biology, pharmacology, medicinal chemistry, clinical medicine, and business development. MEDIFIC has signed a joint research contract with Korea University, Seoul National University and Chungbuk National University, and MOU for collaboration with KMEDI hub. MEDIFIC was selected for a non-clinical development project from Korea Drug Development Fund (KDDF; 2022) and an Innovative Startup Project from the Ministry of SMEs and Startups of Korea (2023). Our Professionality ■ Discovery and validation of pharmacological target for the CSC-targeted therapy ■ Hit discovery and lead optimization of small molecule drugs ■ Drug screening system to validate the efficacy and MoA for innovative but undruggable target proteins ■ In vivo evaluation of PK/PD using the GBM orthotopic xenograft mouse model and solid tumor SC xenograft mouse model. | MEDIFIC is a pre-clinical stage biotech company developing first-in-class anti-cancer treatments targeting cancer stem cells (CSCs). MEDIFIC was founded in 2018, based on expertise in brain cancer and CSC research for over 20 years from academia (Korea University). Motivated by the high unmet medical need for breakthrough treatment to suppress CSC-driven recurrence in GBM, MEDIFIC is dedicated to developing first-in-class CSC-targeted treatment. Furthermore, we seek to expand indications to a variety of cancers, such as liver and lung cancers, to elevate the potential value of our pipelines.
MEDIHUB, Inc
MEDIHUB develops innovative medical devices that enhance safe and precise drug delivery. Our Digital Painless Automatic Injector, created with Seoul National University Hospital, has achieved global trust and over $7.2M in exports. We’re expanding into dermatology, TMJ therapy, painless hair transplantation, and the self-injection market.